Dosage form comprising parallel lamine
AssigneeAlza Corporation
InventorsDavid E. Edgren, Judy A. Magruder, Gurdish K. Bhatti
Life of this patent
Estimating the term…
Abstract
A bilaminated dosage form is disclosed comprising at least 30 weight percent cellulose ether, a first lamina and a second lamina with each lamina comprising a different cellulose ether formulation, and a drug in at least one of the lamina.
Claims26
A bilaminated system for delivering a beneficial drug to an environment of use, the bilaminated system comprising:
- 30 weight percent to 90 weight percent of a cellulose ether composition:
- said composition comprising a first lamina comprising up to 80 weight percent of a cellulose ether selected from the group of hydroxypropylmethylcellulose ethers comprising a degree of polymerization of about 50 to 1260, a viscosity of about 3 to 100,000 centipoises, and a number average molecular weight of 9,000 to 250,000, and a dosage amount of from 0.05 ng to 5 g of a beneficial drug;
- and, a second lamina in contacting arrangement with the first lamina, the second lamina comprising up to 50 weight percent of a different cellulose ether composition comprising a hydroxypropylcellulose comprising a hydroxyproxyl content of 7% to 16%.
A bilaminated system for delivering a beneficial drug to an environment of use, the bilaminated system comprising:
- (a) a cellulose ether composition comprising:
- (b) a first lamina comprising up to 80 weight percent of a cellulose ether selected from the group consisting of hydroxypropylmethylcellulose ethers comprising a degree of polymerization of 40 to 1600, a viscosity of 2 to 225,000 and a number average molecular weight of 9,000 to 307,200;
- and (c) a second lamina in parallel mated relation with the first lamina, the second lamina comprising up to 50 weight percent of a cellulose ether composition comprising a hydroxypropylcellulose comprising a hydroxypropoxyl content of 7 percent to 16 percent, and a dosage unit amount of 25 ng to 1.5 g of a beneficial drug.
A bilaminated system for delivering a beneficial drug to an environment of use, wherein the bilaminated system comprises:
- (a) at least 30 weight percent of a cellulose ether composition present in a first lamina and a second lamina;
- wherein the first lamina comprises up to 85 weight percent of at least one hydropropylmethylcellulose comprising a number average molecular weight of from 9,000 to 250,000;
- and wherein the second lamina comprises up to 85 weight percent of hydroxypropylmethylcellulose comprising a different number average molecular weight of from 9,000 to 250,000 and a dosage amount of from 25 ng to 1.5 g of a beneficial drug.
A bilaminated system for delivering a beneficial drug to an environment of use, wherein the bilaminated system comprises:
- (a) 30 weight percent to 90 weight percent of a cellulose ether composition comprising a first lamina and a second lamina;
- said first lamina comprising a cellulose ether selected from a hydropropylmethylcellulose ether comprising a number average molecular weight of from 9,000 to 250,000 and a dosage unit amount of 25 ng to 1.5 g of a beneficial drug;
- and wherein the second lamina comprises a cellulose ether selected from a hydroxypropylmethylcellulose ether comprising a different number average molecular weight of from 9,000 to 250,000.
A bilaminated system for delivering the beneficial drug ibuprofen to an environment of use, wherein the bilaminated system comprises:
- a first lamina comprising up to 80 weight percent of a hydroxypropylmethylcellulose comprising a degree of polymerization of about 50 to 1260, a viscosity of about 3 to 100,000 centipoises and a number average molecular weight of 9,000 to 250,000, and a dosage amount of from 25 ng to 1.5 g of ibuprofen;
- and a second lamina comprising up to 50 weight percent of a hydroxypropylcellulose comprising from 7 percent to 16 percent hydroxypropoxyl, and a dosage amount of from 25 ng to 1.5 g of ibuprofen.
A bilaminated system for delivering a beneficial drug to an environment of use wherein the bilaminated system comprises:
- a first lamina comprising up to 80 weight percent of a hydroxypropylmethylcellulose comprising a degree of polymerization of about 50 to 1260, a viscosity of about 3 to 100,000 centipoises and a number average molecular weight of 9,000 to 250,000;
- a second lamina comprising a hydroxypropylcellulose comprising a hydroxypropoxyl content of 7% to 16%;
- and wherein the bilaminated system comprises from 25 ng to 1.5 g of a beneficial drug selected from the group consisting of cimentidine, umetidine, ranitidine, naproxen, estrogenic, progestiational, captopril, diltiazom, and isosorbide dinitrate.
Dependencies are inferred from the claim text.